• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲状腺细针穿刺活检结果不确定的甲状腺结节中超声特征与Afirma基因表达分类器结果之间的关系

Relationship Between Sonographic Characteristics and Afirma Gene Expression Classifier Results in Thyroid Nodules With Indeterminate Fine-Needle Aspiration Cytopathology.

作者信息

Zhu Qing-Li, Faquin William C, Samir Anthony E

机构信息

1 Department of Ultrasound, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.

2 Department of Radiology, Abdominal Imaging and Intervention, Massachusetts General Hospital, Harvard Medical School, White 270, 55 Fruit St, Boston, MA 02114.

出版信息

AJR Am J Roentgenol. 2015 Oct;205(4):861-5. doi: 10.2214/AJR.14.13984.

DOI:10.2214/AJR.14.13984
PMID:26397337
Abstract

OBJECTIVE

The purpose of this article is to investigate whether specific clinical and sonographic characteristics are predictive of a benign Afirma test result.

MATERIALS AND METHODS

We conducted a retrospective study of Afirma gene expression classifier analysis performed in 44 patients with 45 indeterminate thyroid fine-needle aspiration (FNA) cytologic results between March 2013 and April 2014. Of these, 33 of 45 nodules (73.3%) were repeat atypia of undetermined significance (AUS) and follicular lesions of undetermined significance (FLUS), or follicular neoplasm (FN) and suspicious for a follicular neoplasm (SFN) before Afirma testing.

RESULTS

Of the 45 nodules, 21 (46.7%) were cytologically diagnosed as FLUS, 16 (35.6%) were diagnosed as AUS, and eight (17.8%) were diagnosed as FN or SFN. By Afirma testing, 23 of the 45 nodules (51.1%) were benign, 21 (46.7%) were suspicious, and one (2.2%) had nondiagnostic results. The mean (± SD) nodule size was smaller in the Afirma-benign group than in the Afirma-suspicious group (1.8 ± 0.8 cm [95% CI, 1.4-2.1] vs 2.2 ± 0.8 cm [95% CI, 1.8-2.6]; p < 0.035). No sonographic feature was statistically significantly different between the Afirma-benign and -suspicious groups, including nodule solidity (p = 0.225), echogenicity (p = 0.543), calcification (p = 0.542), and hypervascularity (p = 0.976). All nodules were ovoid shaped and had circumscribed margins in both Afirma groups.

CONCLUSION

Smaller nodule size was the only characteristic associated with a benign diagnosis on Afirma testing. Sonographic characteristics are not helpful in cases that had a repeat indeterminate FNA finding before Afirma testing.

摘要

目的

本文旨在研究特定的临床和超声特征是否能预测阿菲玛检测结果为良性。

材料与方法

我们对2013年3月至2014年4月期间44例患者的45份甲状腺细针穿刺(FNA)细胞学检查结果为不确定的病例进行了阿菲玛基因表达分类分析的回顾性研究。其中,45个结节中的33个(73.3%)在阿菲玛检测前为意义不明确的非典型增生(AUS)、意义不明确的滤泡性病变(FLUS)、滤泡性腺瘤(FN)或可疑滤泡性腺瘤(SFN)。

结果

45个结节中,21个(46.7%)细胞学诊断为FLUS,16个(35.6%)诊断为AUS,8个(17.8%)诊断为FN或SFN。通过阿菲玛检测,45个结节中有23个(51.1%)为良性,21个(46.7%)为可疑,1个(2.2%)结果无法诊断。阿菲玛检测为良性组的结节平均(±标准差)大小小于阿菲玛检测为可疑组(1.8±0.8 cm [95% CI,1.4 - 2.1] 对比 2.2±0.8 cm [95% CI,1.8 - 2.6];p < 0.035)。阿菲玛检测为良性组和可疑组之间的超声特征在统计学上无显著差异,包括结节实性(p =

相似文献

1
Relationship Between Sonographic Characteristics and Afirma Gene Expression Classifier Results in Thyroid Nodules With Indeterminate Fine-Needle Aspiration Cytopathology.甲状腺细针穿刺活检结果不确定的甲状腺结节中超声特征与Afirma基因表达分类器结果之间的关系
AJR Am J Roentgenol. 2015 Oct;205(4):861-5. doi: 10.2214/AJR.14.13984.
2
Implications of a suspicious afirma test result in thyroid fine-needle aspiration cytology: an institutional experience.甲状腺细针穿刺细胞学检查中可疑阳性结果的意义:一项机构经验。
Cancer Cytopathol. 2014 Oct;122(10):737-44. doi: 10.1002/cncy.21455. Epub 2014 Aug 13.
3
Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.甲状腺结节细胞诊断中异型性的限定词与不同的Afirma基因表达分类器结果及临床结局相关。
Cancer Cytopathol. 2017 May;125(5):313-322. doi: 10.1002/cncy.21827. Epub 2017 Feb 2.
4
Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier.甲状腺乳头状癌的非侵袭性滤泡型变体与Afirma基因表达分类器
Thyroid. 2016 Jul;26(7):911-5. doi: 10.1089/thy.2015.0644.
5
An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.一项关于基因表达分类器(Afirma)在评估细胞学不确定的甲状腺结节中的独立研究。
J Clin Endocrinol Metab. 2014 Nov;99(11):4069-77. doi: 10.1210/jc.2013-3584. Epub 2014 Apr 29.
6
Multicenter clinical experience with the Afirma gene expression classifier.多中心临床应用 Afirma 基因表达分类器的经验。
J Clin Endocrinol Metab. 2014 Jan;99(1):119-25. doi: 10.1210/jc.2013-2482. Epub 2013 Dec 20.
7
The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the performance of the Afirma gene expression classifier.具有乳头样核特征的非侵袭性滤泡性甲状腺肿瘤对Afirma基因表达分类器性能的影响。
Cancer Cytopathol. 2017 Sep;125(9):683-691. doi: 10.1002/cncy.21879. Epub 2017 May 24.
8
Risk stratification of cytologically indeterminate thyroid nodules with nondiagnostic or benign cytology on repeat FNA: Implications for molecular testing and surveillance.重复细针穿刺细胞学检查显示非诊断性或良性的甲状腺结节细胞学分型不确定患者的风险分层:对分子检测和监测的影响。
Cancer Cytopathol. 2023 May;131(5):313-324. doi: 10.1002/cncy.22684. Epub 2023 Feb 15.
9
UTILITY OF AFIRMA GENE EXPRESSION CLASSIFIER FOR EVALUATION OF INDETERMINATE THYROID NODULES AND CORRELATION WITH ULTRASOUND RISK ASSESSMENT: SINGLE INSTITUTIONAL EXPERIENCE.AFIRMA 基因表达分类器在评估不确定甲状腺结节中的效用及其与超声风险评估的相关性:单机构经验。
Endocr Pract. 2020 May;26(5):543-551. doi: 10.4158/EP-2019-0350. Epub 2020 Jan 22.
10
Has Afirma gene expression classifier testing refined the indeterminate thyroid category in cytology?Afirma基因表达分类器检测是否优化了甲状腺细胞学检查中的不确定类别?
Cancer Cytopathol. 2016 Feb;124(2):100-9. doi: 10.1002/cncy.21624. Epub 2015 Sep 30.

引用本文的文献

1
Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.Thyroseq v3、Afiirma GSC 和 microRNA 面板与术前诊断不确定甲状腺结节的先前分子检测的比较:系统评价和荟萃分析。
Front Endocrinol (Lausanne). 2021 May 13;12:649522. doi: 10.3389/fendo.2021.649522. eCollection 2021.
2
Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing.重复细针抽吸细胞学检查可优化甲状腺结节 Afirma 基因表达分类器检测的选择。
Thyroid. 2021 Aug;31(8):1253-1263. doi: 10.1089/thy.2020.0969. Epub 2021 Jun 22.
3
Extending expressed RNA genomics from surgical decision making for cytologically indeterminate thyroid nodules to targeting therapies for metastatic thyroid cancer.
将表达 RNA 基因组学从针对细胞学不确定的甲状腺结节的手术决策扩展到针对转移性甲状腺癌的靶向治疗。
Cancer Cytopathol. 2019 Jun;127(6):362-369. doi: 10.1002/cncy.22132. Epub 2019 Apr 24.
4
Evaluation of 167 Gene Expression Classifier (GEC) and ThyroSeq v2 Diagnostic Accuracy in the Preoperative Assessment of Indeterminate Thyroid Nodules: Bivariate/HROC Meta-analysis.167 基因表达分类器(GEC)和 ThyroSeq v2 在术前评估甲状腺结节中的诊断准确性评估:双变量/HROC 荟萃分析。
Endocr Pathol. 2019 Mar;30(1):8-15. doi: 10.1007/s12022-018-9560-5.
5
Preoperative Molecular Markers in Thyroid Nodules.甲状腺结节的术前分子标志物
Front Endocrinol (Lausanne). 2018 Apr 18;9:179. doi: 10.3389/fendo.2018.00179. eCollection 2018.
6
Genetic testing for indeterminate thyroid cytology: review and meta-analysis.对不确定甲状腺细胞学的基因检测:综述和荟萃分析。
Endocr Relat Cancer. 2018 Mar;25(3):R163-R177. doi: 10.1530/ERC-17-0405. Epub 2017 Dec 18.
7
Molecular Profiling of Thyroid Nodules: Current Role for the Afirma Gene Expression Classifier on Clinical Decision Making.甲状腺结节的分子剖析:Afirma基因表达分类器在临床决策中的当前作用
Mol Imaging Radionucl Ther. 2017 Feb 9;26(Suppl 1):36-49. doi: 10.4274/2017.26.suppl.05.